What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?

Published:2020-04 Issue:S1 Volume:22 Page:55-68
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Sridhar Vikas S.¹^ORCID,Rahman Habib U.¹,Cherney David Z.I.¹²³^ORCID

Affiliation:

1. Department of Medicine, Division of NephrologyToronto General Hospital, University of Toronto Toronto Ontario Canada

2. Banting and Best Diabetes CentreUniversity of Toronto Toronto Ontario Canada

3. Department of Physiology and Department of Pharmacology & ToxicologyUniversity of Toronto Toronto Ontario Canada

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13965

Reference97 articles.

1. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists

2. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

3. A Big Win for Diabetic Kidney Disease: CREDENCE

4. New and old agents in the management of diabetic nephropathy

5. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?;Diabetes, Obesity and Metabolism;2024-06-20

2. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction;JACC: Heart Failure;2024-01

3. Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes;Diabetes, Obesity and Metabolism;2023-07-28

4. Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials;Diabetes, Obesity and Metabolism;2023-05-15

5. Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes;Diabetes Epidemiology and Management;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3